Grant: A rabdomized, double blind, placebo controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer

  • Basic View
  • XML View
Project Title
A rabdomized, double blind, placebo controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer
 
Principal Investigator Ho, James Chung Man (Principal investigator)
Co-Investigator(s) Dr Wang Julie Kwan Ling (Co-Investigator)
Dr Lam David Chi Leung (Co-Investigator)
Dr Wong Matthew King Yan (Co-Investigator)
Funding Year
2007/2008
 
Amount
288359
 
Panel Medicine
Start Date
21-08-2007
 
Expected Completion
20-09-2009
 
Status
On-going
 
Keywords locally advanced NSCLC, recurrent NSCLC, metastatic NSCLC
Discipline Respiration, Cancer
Grant Type/Funding Scheme Pharmaceutical Industry - General Award
Duration
25
 
[Coming Soon]